WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd., today announced plans to realign its operations in the United States. As part of this restructuring, Eisai Inc. will reduce its workforce by approximately 20 percent across all U.S. functions, eliminating approximately 600 positions in total by April 1, 2011. This organizational restructuring supports Eisai’s global mid-term strategic plan for FY2011-2015, which seeks to transform Eisai’s business into a more efficient and focused organization to better serve its human health care (hhc) mission.
“This restructuring is essential to our remaining competitive in this rapidly changing environment,” said Lonnel Coats, President and CEO of Eisai Inc. “It will enable us to continually make the necessary investments in our science, our people and ultimately our human health care (hhc) mission, while ensuring an adequate return to our shareholders.”
Eisai will focus on accelerating our Oncology portfolio and launch new neuroscience assets in support of our strong presence in this important therapeutic area. The new structure is expected to be in place by the start of FY2011, which begins April 1, 2011. Eisai’s U.S. operations include research and development, manufacturing, sales and marketing, and administrative functions. The company does not have plans to close any of its main offices or facilities.
“We are grateful to our colleagues, each of whom has played an important role in bringing medicines to patients. We are aware of the impact that our reorganization will have on some employees and will work with them to ensure that their transition to new careers is as smooth as possible,” said Mr. Coats.
Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business. Eisai’s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd.
Eisai has a global product creation organization that includes U.S.-based R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina. The company’s areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com.
Eisai Co., Ltd.
Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system.
Lynn Kenney, 201-746-2294
Junichi Asatani, 201-746-2640
KEYWORDS: United States North America New Jersey
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical Professional Services Finance